Esperion Therapeutics (United States)

Recent papers from Esperion Therapeutics (United States)

1. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial InfarctionJournal of the American College of Cardiology · 2017
2. Bempedoic Acid and Incidence of Stroke Among Statin-Intolerant Patients: An Analysis of the Clear Outcomes TrialAtherosclerosis · 2026
3. Bempedoic Acid in Children Aged 6-17 Years With Heterozygous Familial Hypercholesterolemia: A Phase 2 StudyAtherosclerosis · 2026
4. Factors Associated With Enhanced LDL-Cholesterol Lowering With Bempedoic Acid Among Statin-Intolerant Patients From Clear OutcomesAtherosclerosis · 2026
5. Bempedoic Acid Without Background Llt, LDL Cholesterol and Cardiovascular Events: A Secondary Analysis of the Clear Outcomes TrialAtherosclerosis · 2026
6. The Association Between Bempedoic Acid and Risk of Venous Thromboembolism: A Post Hoc Analysis of the Clear Outcomes TrialAtherosclerosis · 2026
7. Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes TrialCirculation · 2026
8. Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic AcidJournal of the American Heart Association · 2026
9. Bempedoic Acid and Venous Thromboembolism Risk Among Statin-Intolerant PatientsJAMA Cardiology · 2026
10. Effect of bempedoic acid in the absence of background lipid-lowering therapy on LDL cholesterol, hsCRP, and cardiovascular outcomes, among statin-intolerant patients: a post-hoc analysis of the CLEAR outcomes trialEuropean Journal of Preventive Cardiology · 2026
11. Sex Differences in Statin Intolerance: Insights From the CLEAR Outcomes TrialClinical Cardiology · 2026
12. Systematic literature review on the real-world effectiveness and safety of bempedoic acidAtherosclerosis Plus · 2026
13. Effect of bempedoic acid on cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver diseaseEuropean Journal of Preventive Cardiology · 2026
14. Frequency of gout adverse events with bempedoic acid or placebo in those receiving uric acid lowering therapies as prophylaxis or treatment after a gout episode - insights from CLEAR outcomesEuropean Heart Journal · 2025
15. LDL-C lowering in patients treated with bempedoic acid in a real-world cohortAtherosclerosis Plus · 2026
16. Recovery from apoptosis in photoreceptor cells: A role for mitophagyCell Death and Disease · 2026
17. Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASHCell Metabolism · 2026
18. Cost-Effectiveness of Bempedoic Acid in High Cardiovascular Risk Patients with Statin Intolerance: An Analysis of the CLEAR Outcomes TrialAmerican Journal of Cardiovascular Drugs · 2025
19. ACLY inhibition promotes tumour immunity and suppresses liver cancerNature · 2025
20. Neuroprotection of photoreceptors by combined inhibition of both Fas and autophagy pathways in P23H miceCell Death and Disease · 2025